In hospital settings, the classification of “Observation Status” is something we frequently encounter. The ramifications for care and cost can be catastrophic.
Learn more, here.
One topic that I am asked about frequently is the lack of transparency regarding healthcare costs, a reality that makes it difficult for consumers to make informed decisions.
This article addresses the topic and provides a few examples of organizations working on the issue.
This article about deadly superbugs is frightening. It’s one of the many reasons we work so hard to prevent our clients from being hospitalized.
Many of our clients are forced to deal with both a major illness as well as the administrative burden of managing their insurance. This article highlights that unfortunate reality.
As professionals who guide Medicare recipients through administrative barriers experienced when accessing care, we found this article very disturbing.
This was a moving piece about the impact of depression and the importance of friendship.
I appreciated this recent commentary regarding paid leave and the caring of the older adults in our lives. Click here to read.
I remain committed to Simmons University for so many reasons, one of which is the university’s research on gender in organizations.
For example, at the last four women’s leadership conferences I attended, “men allyship” was a subject of discussion. This important topic has gained much visibility, both as a role that individual men take up, as well as an organizational strategy for enhancing gender equity. Take a look at some recent findings, here.
My friend and colleague Sue Nemetz is President of The NemetzGroup, a life sciences commercial and strategy advisory firm. Recently, TNG published a fascinating newsletter about rare diseases and the development of medicines to treat them.
“Rare diseases (AKA, ‘orphan diseases’) are unlike any other. For a host of reasons — not the least of which is the human toll these take on those afflicted and their families — the discovery, development, and commercialization of medicines in this area needs to be approached in ways that are different than what one might do with more established diseases affecting much larger populations.”
Read the entire piece here.